Humana heads into the final week of June with an unusual dynamic: the stock is down on the week while analysts are racing to lift their price targets.
The analyst story is the headline this week, and it tells a bullish-leaning tale with caveats. BofA Securities raised its target to $380 on Tuesday — the second time Kevin Fischbeck has lifted targets this month, having moved first from $267 to $340 on June 4. That is a notable shift in conviction from a bellwether firm that remains at Neutral. The broader pattern is the same: Evercore, Mizuho, JPMorgan, Barclays, Morgan Stanley, and UBS have all raised targets over the past four weeks. The direction of travel is uniformly upward. But the ratings tell a more cautious story — the Street remains overwhelmingly Neutral or equivalent, with Morgan Stanley still carrying an Underweight and a $249 target well below the current $359.13 print. The mean target of $304 also sits noticeably below the market price, a function of the stock's sharp 17% rally in June catching analysts behind the move. The bull case rests on 500 basis points of Medicare Advantage margin expansion and CenterWell's 16% pharmacy revenue growth. The bear case is concrete: a $3.5 billion MA Star-ratings headwind that the company itself has flagged as a potential $22 EPS drag in 2026.
Short positioning tells a less urgent story than the fundamental debate implies. At 4.7% of free float, short interest is real but not extreme — and it has fallen 17% over the past month, from roughly 6.8 million shares to 5.6 million. The borrow market is correspondingly relaxed: cost to borrow is just 0.44%, near its lowest level in six weeks, and availability is ample at over 1,700% of current short interest. That combination — declining shorts, cheap borrow, wide availability — suggests the covering that drove much of June's rally is largely done. There is no squeeze pressure here, and no obvious catalyst to force further covering. Options add a mild note of caution: the put/call ratio has climbed to 0.96, about 1.4 standard deviations above its 20-day average of 0.88, its highest reading since mid-June's 1.06 spike. Investors are buying slightly more downside protection than usual, but the level is nowhere near alarming.
The momentum behind the stock is real. EPS momentum ranks in the 91st percentile on a 30-day basis and 78th on 90 days — the forward earnings revision cycle has been strongly positive. The dividend factor scores at the 86th percentile, though the dividend history in the data is stale and reflects payouts last recorded in 2022; income investors should verify the current dividend profile independently. The PE multiple sits at roughly 30x, up about three points over the past month as the stock re-rated faster than estimates moved. Among peers, UNH fell just 0.4% on the week while HUM dropped 2.8%. CVS gained 0.9% and ELV fell 1.7% — Humana's underperformance on the week is modest in that context, but it represents a partial reversal after outperforming peers sharply through most of June.
Institutional holders largely reflect passive and value-oriented ownership, with Dodge & Cox at 9.5%, BlackRock at 8.5%, and Pzena Investment Management adding nearly 1.4 million shares in the most recent quarter — a meaningful active build. Sessa Capital, a smaller hedge fund, added 1.4 million shares as well, taking a 3.1% stake. These are not passive flows; they suggest some active managers were buying into the weakness that preceded June's rally.
The next scheduled catalyst is Q2 earnings on July 29. The most recent print — Q1 on April 29 — delivered a 2.9% one-day gain and a 7.2% five-day move, confirming that positive surprises have been rewarded. What to watch into that date: whether the Star-ratings headwind hardens into guidance revisions, and whether the analysts still at Neutral convert their cautious target upgrades into actual rating changes as the stock trades at or above their revised marks.
See the live data behind this article on ORTEX.
Open HUM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
